HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings

Artelo Biosciences, Inc. (NASDAQ:ARTL) – HC Wainwright decreased their FY2025 earnings per share estimates for Artelo Biosciences in a report released on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($1.84) for the year, down from their prior estimate of ($1.61). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share.

A number of other research analysts have also issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a research note on Thursday, February 27th. LADENBURG THALM/SH SH upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th.

Artelo Biosciences Stock Down 2.0 %

Shares of ARTL stock opened at $1.00 on Thursday. The company has a market cap of $3.23 million, a P/E ratio of -0.35 and a beta of 1.06. The business has a 50 day moving average of $1.17 and a two-hundred day moving average of $1.15. Artelo Biosciences has a 52 week low of $0.91 and a 52 week high of $1.70.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43).

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.